RVL Pharmaceuticals plc Deferred Revenue Recognized
RVL Pharmaceuticals plc reported Deferred Revenue Recognized of $1.10 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2023-08-14
- RVL Pharmaceuticals plc contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $1.80M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month |
|---|---|---|
| 2023-06-30 | $1.10M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $1.80M 10-Q · filed 2023-05-11 | |
| 2022-06-30 | $100.00K 10-Q · filed 2023-08-14 |